{
    "root": "8ff13251-1ffd-4a33-8037-7dc7bfc1f2a2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Heparin Sodium",
    "value": "20250505",
    "ingredients": [
        {
            "name": "HEPARIN SODIUM",
            "code": "ZZ45AB24CA"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "NITROGEN",
            "code": "N762921K75"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "Heparin Sodium Injection is indicated for: \n                  \n                     \n                        •Prophylaxis and treatment of venous thrombosis and pulmonary embolism \n                     \n                        •Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease \n                     \n                        •Atrial fibrillation with embolization \n                     \n                        •Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) \n                     \n                        •Prevention of clotting in arterial and cardiac surgery \n                     \n                        •Prophylaxis and treatment of peripheral arterial embolism \n                     \n                        •Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures",
    "contraindications": "Recommended Adult Dosages: • Therapeutic Anticoagulant Effect with Full-Dose Heparin Sodium Injection † ( 2.3 ) † Based on 150 lb (68 kg) patient. Adjust dose based on laboratory monitoring. Deep Subcutaneous (Intrafat) Injection Use a different site for each injection Initial Dose 5,000 units by intravenous injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously Every 8 hours or Every 12 hours 8,000 to 10,000 units of a concentrated solution 15,000 to 20,000 units of a concentrated solution Intermittent Intravenous Injection Initial dose 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Every 4 to 6 hours 5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Intravenous Infusion Initial dose 5,000 units by intravenous injection Continuous 20,000 to 40,000 units/24 hours in 1,000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion",
    "warningsAndPrecautions": "Heparin Sodium Injection, USP preserved with benzyl alcohol is available as follows: \n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Strength                \n                                 \n                                 (Concentration)                \n                              \n                           \n                           \n                              \n                                 Vial Fill Volume\n                              \n                           \n                           \n                              \n                                 Vial Type\n                              \n                           \n                           \n                              \n                                 Package Factor\n                              \n                           \n                        \n                        \n                           \n                              55154-2827-5\n                           \n                           \n                              5,000 USP units per mL \n                           \n                           \n                              1 mL \n                           \n                           \n                              1 mL Vial \n                           \n                           \n                              Overbagged with 5 x 1 mL vials in each bag, NDC 55154-2827-5\n                           \n                        \n                     \n                  \n                  WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                     Sterile, Nonpyrogenic.\n                     \n                     The container closure is not made with natural rubber latex.\n                  \n                  \n                     Storage Conditions\n                     \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]",
    "adverseReactions": "The use of heparin sodium is contraindicated in patients with the following conditions: \n                  \n                     \n                        •History of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see Warnings and Precautions (5.3)]\n                     \n                     \n                        •Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions (6.1)]\n                     \n                     \n                        •In whom suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) \n                     \n                        •An uncontrolled active bleeding state [see Warnings and Precautions (5.4)], except when this is due to disseminated intravascular coagulation"
}